CD44s and CD44v8-10 isoforms confer acquired resistance to osimertinib by activating the ErbB3/STAT3 signaling pathway-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CD44s and CD44v8-10 isoforms confer acquired resistance to osimertinib by activating the ErbB3/STAT3 signaling pathway

Published:2024-01 Issue: Volume:336 Page:122345
ISSN:0024-3205
Container-title:Life Sciences
language:en
Short-container-title:Life Sciences

Author:

Liu Yi-Nan,Tsai Meng-Feng,Wu Shang-Gin,Chang Tzu-Hua,Shih Jin-Yuan

Funder

National Taiwan University Hospital

Ministry of Science and Technology

Ministry of Science and Technology, Taiwan

Publisher

Elsevier BV

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference39 articles.

1. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC;Ramalingam;N. Engl. J. Med.,2020

2. Understanding mechanisms of resistance in the epithelial growth factor receptor in non-small cell lung Cancer and the role of biopsy at progression;Socinski;Oncologist,2017

3. CD44: structure, function, and association with the malignant process;Naor;Adv. Cancer Res.,1997

4. CD44: from adhesion molecules to signalling regulators;Ponta;Nat. Rev. Mol. Cell Biol.,2003

5. The normal structure and function of CD44 and its role in neoplasia;Sneath;Mol. Pathol.,1998

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prolactin Drives Iron Release from Macrophages and Uptake in Mammary Cancer Cells through CD44;International Journal of Molecular Sciences;2024-08-16

2. ErbB3 is required for hyperaminoacidemia-induced pancreatic α cell hyperplasia;Journal of Biological Chemistry;2024-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3